NIPT is a detection technology that uses the free fetal DNA in the peripheral blood of pregnant women, combined with next-generation sequencing technology and bioinformatics methods to accurately determine whether a fetus has a chromosomal disease. At present, NIPT products on the market mainly detect diseases caused by abnormal numbers of chromosomes 21, 18 and 13.
According to the Genomeweb website, the UK government has approved the inclusion of 21, 18 and 13 non-invasive prenatal screening (NIPT) in routine prenatal screening programs. In January, the National Review Board (NSC) evaluated NIPT as an adjunct screening test—invasive diagnostic tests for high-risk women replaced by NIPT. The new policy of the British government on NIPT is based on previous assessments.
British Health Minister Philip Dunne said in a recent notice that "we hope women can get safe screening tests, so according to clinical evidence, we have approved NIPT in Down syndrome, Edwards syndrome and Padua's synthesis. Used in the prenatal diagnosis of the levy, it is hoped that by providing non-invasive prenatal screening techniques, the number of pregnant women receiving invasive prenatal screening will be reduced, reducing the risk of abortion."
According to the UK Ministry of Health, approximately 10,000 pregnant women are provided with invasive prenatal diagnostic tests (amniocentesis or chorionic villus sampling) each year, and in fact approximately 7,900 pregnant women receive this diagnosis. Now the UK government wants NIPT to replace invasive diagnostic tests, reducing the number of people receiving invasive trials to 1400/year. It is important to reduce the number of abortions associated with it from 46 to 3.
Anne Mackie, director of the NSC program in the UK, said in the announcement, "We will strictly manage the full implementation of NIPT to better understand the impact of screening results on couples making pregnancy decisions. We are developing comprehensive details of NIPT promotion, including The number of websites involved and the collection of information and results."
The UK plans to fully promote NIPT within three years, including training of personnel. The UK Ministry of Health expects NIPT to be included in the UK National Health Service (NHS) system in 2018 or 2019. The UK NSC will continue to evaluate the NIPT and, if necessary, revise the implementation policy.
However, there are already some laboratories in the UK that offer NIPT under the NHS system, such as St. George's School of Medicine, North East Thames Regional Genetics Laboratory, and the NIPT based on Premaitha Health's Iona test at St. George's School of Medicine. Premaitha said recently that Iona testing is currently used in more than 50 NHS facilities.
NIPT replaces traditional three-body screening technology just around the corner
Modified Soybean Pholipid,Modified Soybean Lecithin Oil,Modified Soy Lecithin Oil,Modified Soy Lecithin
Jiangsu Chenwei Biology and Technology Co. LTD , https://www.cwsoybean.com